Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.80 +0.17 (+0.58%)
Streaming Delayed Price Updated: 2:10 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,183,843
Open 28.65
Bid (Size) 28.79 (14)
Ask (Size) 28.80 (107)
Prev. Close 28.63
Today's Range 28.59 - 28.96
52wk Range 28.30 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 5.70%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A weekly look at top trending tickers seeing increased attention from Benzinga users. 
Via Benzinga
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
It's already planning to get back on the horse and make another attempt. 
Via The Motley Fool

Performance

YTD
-43.83%
-43.83%
1 Month
-7.86%
-7.86%
3 Month
-16.00%
-16.00%
6 Month
-26.34%
-26.34%
1 Year
-42.69%
-42.69%

More News

Read More
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
7 Tech Stocks to Light Up Your Portfolio This Holiday Season
Via InvestorPlace
This Is What Whales Are Betting On Pfizer
Via Benzinga
Is Pfizer Stock a Buy Now?
Via The Motley Fool
7 F-Rated Stocks to Sell in December
Via InvestorPlace
Will There Be A Recession In 2024?
Via Talk Markets
Topics Economy
Exposures Economy
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
Via Benzinga
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Via SBWire
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
Via The Motley Fool
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Via Benzinga
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Via Benzinga
Topics Stocks
Exposures US Equities
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
Via Benzinga
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Via MarketBeat
Diamonds in the Rough: 3 Undervalued Stocks with Huge Upside
Via InvestorPlace
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
Via Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
Via InvestorPlace
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
Via InvestorPlace
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.